Real‐world use of anifrolumab in refractory cutaneous lupus: case series and review of the literature

Documenti analoghi

• Type I IFN receptor blockade by anifrolumab reduces cutaneous lupus in monogenic SLE
  di: Julian Steininger, et al.
  Pubblicazione: (2025)
• Acquired perforating dermatoses and cabozantinib: A novel cutaneous toxicity
  di: Diego Soto‐García, et al.
  Pubblicazione: (2024)
• Selective JAK1 inhibition with abrocitinib in refractory disseminated granuloma annulare: A descriptive real‐world case series
  di: Gaetano Licata, et al.
  Pubblicazione: (2026)
• Successful treatment of subacute cutaneous lupus erythematosus with the TYK‐2 inhibitor deucravacitinib in a patient with concomitant psoriasis vulgaris
  di: Katharina Assaf, et al.
  Pubblicazione: (2025)
• Is Kaposi sarcoma a novel comorbidity of cutaneous lymphoma? A systematic review of the literature
  di: Rose K. C. Moritz, et al.
  Pubblicazione: (2025)